Amino alcohol compounds or phosphonic acid derivatives thereof

1. A method for the treatment of an immunology-related disease selected from the group consisting of Crohn's disease, ulcerative colitis, multiple sclerosis, atopic dermatitis, insulin dependent diabetes mellitus, glomerular nephritis and rejection of a transplanted organ or transplanted skin, in a mammal in need thereof which comprises administering to said mammal a pharmaceutically effective amount of a compound, a pharmacologically acceptable salt of the compound or a pharmacologically acceptable ester of the compound, wherein the compound is a compound having a formula (Ia)

wherein R 1 and R 2 are each a hydrogen atom;

R 3 is a hydrogen atom;

R 4 is a C 1 -C 2 alkyl group;

n is 2;

X is ═N—D, wherein D is a hydrogen atom, a C 1 -C 4 alkyl group or a phenyl group;

Y is an ethylene group, an ethynylene group, a group of a formula CO—CH 2 or a phenylene group;

Z is an ethylene group or a trimethylene group;

R 5 is an unsubstituted C 3 -C 10 cycloalkyl group, an unsubstituted C 6 -C 10 aryl group, or a C 3 -C 10 cycloalkyl group or a C 6 -C 10 aryl group substituted with from 1 to 3 substituents selected from the group consisting of a halogen atom, a lower alkyl group, a halogeno lower alkyl group and a lower alkoxy group; and

R 6 and R 7 are each a hydrogen atom.

2. The method according to claim 1 , wherein the mammal is a human.

3. The method according to claim 2 , wherein, in the compound, R 4 is a methyl group, or a pharmacologically acceptable salt thereof.

4. The method according to claim 3 or a pharmacologically acceptable salt thereof, wherein, in the compound, X is a group of a formula ═N—CH 3 , or a pharmacologically acceptable salt thereof.

5. The method according to claim 2 , wherein said compound is 2-amino-2-methyl-4-{1-methyl-5-[4-(3,4-dimethylphenyl)butanoyl]pyrrol-2-yl}butan-1-ol, or a pharmacologically acceptable salt thereof.

6. The method according to claim 2 , wherein said compound is 2-amino-2-methyl-4-{1-methyl-5-[4-(3,5-dimethylphenyl)butanoyl]pyrrol-2-yl}butan-1-ol, or a pharmacologically acceptable salt thereof.

7. The method according to claim 2 , wherein said compound is 2-amino-2-methyl-4-{1-methyl-5-[4-(3-trifluoromethylphenyl)butanoyl]pyrrol-2-yl}butan-1-ol, or a pharmacologically acceptable salt thereof.

8. The method according to claim 2 , wherein said compound is 2-amino-2-methyl-4-{1-methyl-5-[4-(4-trifluoromethylphenyl)butanoyl]pyrrol-2-yl}butan-1-ol.

9. The method according to claim 2 , wherein said compound is 2-amino-2-methyl-4-{1-methyl-5-[4-(4-methylphenyl)butanoyl]pyrrol-2-yl}butan-1-ol.

10. The method according to claim 2 , wherein said compound is 2-amino-2-methyl-4-{1-methyl-5-[4-(4-methoxyphenyl)butanoyl]pyrrol-2-yl}butan-1-ol.

11. The method according to claim 2 , wherein said compound is 2-amino-2-methyl-4-{1-methyl-5-[4-(3-methylphenyl)butyl]pyrrol-2-yl}butan-1-ol.

12. The method according to claim 2 , wherein said compound is 2-amino-2-methyl-4-{1-methyl-5-[4-(3,4-dimethylphenyl)butyl]pyrrol-2-yl}butan-1-ol.

13. The method according to claim 2 , wherein said compound is 2-amino-2-methyl-4-{1-methyl-5-[4-(3,5-dimethylphenyl)butyl]pyrrol-2-yl}butan-1-ol.

14. The method according to claim 2 , wherein said compound is 2-amino-2-methyl-4-{1-methyl-5-[4-(3-trifluoromethylphenyl)butyl]pyrrol-2-yl}butan-1-ol.

15. The method according to claim 2 , wherein R 1 , R 2 and R 3 are each a hydrogen atom, R 4 is a methyl group, n is 2 and Y—Z—R 5 is (O—(CH 2 ) 3 -(4-F-phenyl).

16. The method according to claim 2 , wherein the compound is selected from the group consisting of

2-amino-2-methyl-4-{1-methyl-5-[4-(3,4-dimethylphenyl)butanoyl]pyrrol-2-yl}butan-1-ol;

2-amino-2-methyl-4-{1-methyl-5-[4-(3,5-dimethylphenyl-)butanoyl]pyrrol-2-yl}butan-1-ol;

2-amino-2-methyl-4-{1-methyl-5-[4-(3-trifluoromethylphenyl)butanoyl]pyrrol-2-yl}butan-1-ol;

2-amino-2-methyl-4-{1-methyl-5-[4-(4-trifluoromethylphenyl)butanoyl]pyrrol-2-yl}butan-1-ol;

2-amino-2-methyl-4-{1-methyl-5-[4-(4-methylphenyl)butanoyl]pyrrol-2-yl}butan-1-ol;

2-amino-2-methyl-4-{1-methyl-5-[4-(4-methoxyphenyl)butanoyl]pyrrol-2-yl}butan-1-ol;

2-amino-2-methyl-4-{1-methyl-5-[4-(3-methylphenyl)butyl]pyrrol-2-yl}butan-1-ol;

2-amino-2-methyl-4-{1-methyl-5-[4-(3,4-dimethylphenyl)butyl]pyrrol-2-yl}butan-1-ol;

2-amino-2-methyl-4-{1-methyl-5-[4-(3,5-dimethylphenyl)butyl]pyrrol-2-yl}butan-1-ol;

2-amino-2-methyl-4-{1-methyl-5-[4-(3-trifluoromethylphenyl)butyl]pyrrol-2-yl}butan-1-ol; and

a compound of the formula (Ia), wherein R 1 , R 2 and R 3 are each a hydrogen atom, R 4 is a methyl group, n is 2 and Y—Z—R 5 is —CO—(CH 2 ) 3 -(4-F-phenyl),

or a pharmacologically acceptable salt thereof.

17. The method according to claim 5 , wherein the configuration at the carbon atom to which the group of the formula —NR 1 R 2 attaches is the R configuration, or a pharmacologically acceptable salt thereof.

18. The method according to claim 6 , wherein the configuration at the carbon atom to which the group of the formula —NR 1 R 2 attaches is the R configuration, or a pharmacologically acceptable salt thereof.

19. The method according to claim 7 , wherein the configuration at the carbon atom to which the group of the formula —NR 1 R 2 attaches is the R configuration, or a pharmacologically acceptable salt thereof.

20. The method according to claim 8 , wherein the configuration at the carbon atom to which the group of the formula —NR 1 R 2 attaches is the R configuration, or a pharmacologically acceptable salt thereof.

21. The method according to claim 9 , wherein the configuration at the carbon atom to which the group of the formula NR 1 R 2 attaches is the R configuration, or a pharmacologically acceptable salt thereof.

22. The method according to claim 10 , wherein the configuration at the carbon atom to which the group of the formula —NR 1 R 2 attaches is the R configuration, or a pharmacologically acceptable salt thereof.

23. The method according to claim 11 , wherein the configuration at the carbon atom to which the group of the formula —NR 1 R 2 attaches is the R configuration, or a pharmacologically acceptable salt thereof.

24. The method according to claim 12 , wherein the configuration at the carbon atom to which the group of the formula —NR 1 R 2 attaches is the R configuration, or a pharmacologically acceptable salt thereof.

25. The method according to claim 13 , wherein the configuration at the carbon atom to which the group of the formula —NR 1 R 2 attaches is the R configuration, or a pharmacologically acceptable salt thereof.

26. The method according to claim 14 , wherein the configuration at the carbon atom to which the group of the formula —NR 1 R 2 attaches is the R configuration, or a pharmacologically acceptable salt thereof.

27. The method according to claim 15 , wherein the configuration at the carbon atom to which the group of the formula —NR 1 R 2 attaches is the R configuration, or a pharmacologically acceptable salt thereof.

28. The method according to claim 2 , wherein the disease is Crohn's disease or ulcerative colitis.

29. The method according to claim 2 , wherein the disease is multiple sclerosis.

30. The method according to claim 2 , wherein the disease is atopic dermatitis.

31. The method according to claim 2 , wherein the disease is insulin dependent diabetes mellitus.

32. The method according to claim 2 , wherein the disease is glomerular nephritis.

33. The method according to claim 2 , wherein the disease is rejection of a transplanted organ or transplanted skin.

34. The method according to claim 1 , wherein the disease is a host versus graft reaction.

35. The method of claim 9 , wherein the disease is multiple sclerosis.

36. The method according to claim 9 , wherein the disease is atopic dermatitis.

37. The method according to claim 9 , wherein the disease is insulin dependent diabetes mellitus.

38. The method according to claim 9 , wherein the disease is glomerular nephritis.

39. The method according to claim 9 , wherein the disease is rejection of a transplanted organ or transplanted skin.

40. The method according to claim 9 , wherein the disease is Crohn's disease or ulcerative colitis.

41. The method according to claim 2 , wherein the disease is a host versus graft reaction.

42. The method according to claim 9 , wherein the disease is a host versus graft reaction.

43. The method according to claim 5 , wherein the disease is Crohn's disease or ulcerative colitis.

44. The method of claim 5 , wherein the disease is multiple sclerosis.

45. The method according to claim 5 , wherein the disease is atopic dermatitis.

46. The method according to claim 5 , wherein the disease is insulin dependent diabetes mellitus.

47. The method according to claim 5 , wherein the disease is glomerular nephritis.

48. The method according to claim 5 , wherein the disease is rejection of a transplanted organ or transplanted skin.

49. The method according to claim 5 , wherein the disease is a host versus graft reaction.

50. The method according to claim 10 , wherein the disease is Crohn's disease or ulcerative colitis.

51. The method of claim 10 , wherein the disease is multiple sclerosis.

52. The method according to claim 10 , wherein the disease is atopic dermatitis.

53. The method according to claim 10 , wherein the disease is insulin dependent diabetes mellitus.

54. The method according to claim 10 , wherein the disease is glomerular nephritis.

55. The method according to claim 10 , wherein the disease is rejection of a transplanted organ or transplanted skin.

56. The method according to claim 10 , wherein the disease is a host versus graft reaction.